Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD

NCT04968184 is registered in ClinicalTrials.gov with KBP Biosciences as lead sponsor.

NCT NCT04968184
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04968184 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD
Lead sponsor
KBP Biosciences
Phase
Phase 3
Overall status
Terminated
Start date
November 5, 2021
Completion date
July 10, 2024
Enrollment
652 (actual)
Sites
215

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney diseases